Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms
D Pantazi, AD Tselepis - Thrombosis Research, 2022 - Elsevier
Cancer treatment is associated with various side effects of antitumor agents, which increase
the morbidity and mortality of these patients. Cardiovascular complications are considered to …
the morbidity and mortality of these patients. Cardiovascular complications are considered to …
Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies
D Pantazi, D Alivertis, AD Tselepis - Current Treatment Options in …, 2024 - Springer
Opinion Statement Cancer-associated thrombosis (CAT) has been identified as the second
most prevalent cause of death after cancer itself. Moreover, the risk of thrombotic events in …
most prevalent cause of death after cancer itself. Moreover, the risk of thrombotic events in …
Synthesis of novel nilotinib analogues and biological evaluation of their antiplatelet activity and functionality towards cancer cell proliferation in vitro
L Pechlivani, N Ntemou, D Pantazi, D Alivertis… - Pharmaceuticals, 2024 - mdpi.com
Nilotinib, a second-generation tyrosine kinase inhibitor for the treatment of chronic
myelogenous leukemia (CML), inhibits Bcr-Abl tyrosine kinase activity and proliferation of …
myelogenous leukemia (CML), inhibits Bcr-Abl tyrosine kinase activity and proliferation of …
Expressing Enhanced Inhibitory Effects toward Arachidonic Acid Induced Platelet Activation: Design, Synthesis, DFT Calculations and in vitro Evaluation of Imatinib …
A Kosma, D Pantazi, P Voulgari, N Ntemou… - …, 2023 - Wiley Online Library
Encouraged by the excellent antiplatelet properties of novel imatinib and nilotinib analogues
in our previous study and based on a fact that slight structural changes, such as the …
in our previous study and based on a fact that slight structural changes, such as the …
Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib
P Voulgari, D Alivertis, K Skobridis - Helvetica Chimica Acta, 2021 - Wiley Online Library
Osimertinib, a third generation potent and specific EGFR inhibitor is an important drug
against many forms of cancer. It was synthesized by an improved and highly efficient …
against many forms of cancer. It was synthesized by an improved and highly efficient …